Table 2.
Comparison of baseline features in patients with and without renal tubular dysfunction (RTD)
| Features (at time of starting therapy) | With RTD (n = 7) | Without RTD (n = 44) | P-value |
|---|---|---|---|
| Sex (male) | 84% | 84% | 0.91 |
| Age (years)* | 58 (16) | 44 (12) | 0.01 |
| Race | |||
| White | 71% | 39% | 0.17† |
| Black | 14% | 9% | |
| Asian | 14% | 52% | |
| Diabetes (DM) | 14% | 7% | 0.49‡ |
| Hypertension (HTN) | 57% | 34% | 0.24‡ |
| Renal disease (RD) | 0% | 2% | 1.00‡ |
| DM or HTN or RD | 57% | 39% | 0.41‡ |
| ALT (U/L)* | 107 (60) | 155 (202) | 0.54 |
| AST (U/L)* | 107 (89) | 102 (130) | 0.92 |
| Alk P (U/L)* | 100 (52) | 75 (21) | 0.02 |
| Albumin (g/dL)* | 3.6 (0.4) | 3.8 (0.4) | 0.12 |
| Bilirubin (mg/dL)* | 1.3 (1.6) | 1.0 (0.5) | 0.29 |
| Creatinine (mg/dL)* | 0.97 (0.23) | 0.87 (0.18) | 0.18 |
| GFR (mL/min)* | 82 (13) | 97 (21) | 0.08 |
| Phosphate (mg/dL)* | 3.3 (0.6) | 3.4 (0.5) | 0.61 |
| Uric Acid (mg/dL)* | 5.2 (0.9) | 5.4 (0.9) | 0.72 |
| Proteinuria (trace or greater) | 0% | 7% | 1.00‡ |
| HBV DNA (log10 copies/mL)* | 7.97 (1.28) | 7.83 (1.54) | 0.85 |
| HBeAg | 86% | 75% | 1.00‡ |
| Liver histology | |||
| HAI score* | 7 (3) | 8 (3) | 0.36 |
| Ishak Fibrosis* | 3 (2) | 3 (2) | 0.77 |
| Cirrhosis | 0% | 20% | 0.57‡ |
| Concurrent lamivudine | 71% | 50% | 0.42‡ |
| Lamivudine resistance | 29% | 23% | 0.66‡ |
| Duration of therapy (years)* | 5.3 | 6.5 | 0.22 |
Alk P, alkaline phosphatase; GFR, glomerular filtration rate as estimated by MDRD equation; HAI, histology activity index (ranging from 0 to 18).
*
Mean (standard deviation).
†
Chi-square test.
‡
Fisher’s exact test; all other P-values are from t-tests.